MOUNTAIN VIEW, Calif. (AP) ¿ Vivus Inc. reported a smaller first-quarter loss on a dip in development costs for the obesity treatment candidate Qnexa. The biopharmaceutical company said late Monday it lost $6.8 million, or 10 cents per share, in the three months ended March 31 compared with a loss of $7.1 million, or 12 cents per share, a year ago. Revenue slipped to $22.2 million from $22.7 million. Analysts polled by Thomson Reuters expected a smaller loss of 7 cents per share on hgiher revenue of $23.7 million. The estimates typically exclude one-time items. The revenue mainly came from the sale in 2007 of the spray-on hot flash treatment Evamist to K-V Pharmaceutical. Meanwhile, costs dipped on lower development expenses for Qnexa. The company is also developing vanafil as an erectile dysfunction treatment.
More from Technology
Netflix Shares Pop as Q3 Earnings, Subscriber Adds Beat Estimates
Netflix's third quarter was strong, but the fourth quarter is currently looking to be weaker than analysts expected.
IBM Shares Fall as Q3 Adjusted Net Income Beats Estimate, Revenue Up Short
The company posted a 14% increase in cloud revenue to $5 billion while its global business services segment brought in $4.1 billion.
Richly-Valued Software Firms Face a Small Margin of Error -- Just Ask Workday
Workday is down sharply after indicating its core HCM software business will see slowing growth, and it's taking many enterprise software peers lower with it.
KBR Is Poised to Resume Its Advance - Here's Our Strategy
Let's check the charts and indicators of KBR to see if we want to join in from the long side.